Citral: A monoterpene with prophylactic and therapeutic anti-nociceptive effects in experimental models of acute and chronic pain

• Published in: European journal of pharmacology 2014-08, Vol.736, p.16-25
• Main Authors: Nishijima, Catarine M., Ganev, Ellen G., Mazzardo-Martins, Leidiane, Martins, Daniel F., Rocha, Lúcia R.M., Santos, Adair R.S., Hiruma-Lima, Clelia A.
• Format: Article
• Language: English
• Subjects: Acute Pain - chemically induced; Acute Pain - drug therapy; Acute Pain - metabolism; Analgesics - pharmacology; Analgesics - therapeutic use; Animals; Capsaicin; Chronic pain; Chronic Pain - drug therapy; Chronic Pain - etiology; Chronic Pain - metabolism; Chronic regional pain syndrome; Citral; Excitatory Amino Acids; Formaldehyde; Gastro-protective effect; Glutamic Acid; Hyperalgesia - drug therapy; Hyperalgesia - metabolism; Ischemia - complications; Ketanserin - pharmacology; Male; Mice; Monoterpenes - pharmacology; Monoterpenes - therapeutic use; Neuralgia - drug therapy; Neuralgia - metabolism; Neuropathic pain; Pain, Postoperative - drug therapy; Pain, Postoperative - metabolism; Postoperative pain; Rats, Wistar; Receptor, Serotonin, 5-HT2A - metabolism; Serotonin 5-HT2 Receptor Antagonists - pharmacology; Stomach Ulcer - drug therapy; Stomach Ulcer - metabolism; Substance P; Tetradecanoylphorbol Acetate; Tumor Necrosis Factor-alpha
• ISSN: 0014-2999; 1879-0712
• DOI: 10.1016/j.ejphar.2014.04.029

Citral (3,7-dimethyl-2,6-octadienal) is an open-chain monoterpenoid present in the essential oils of several medicinal plants. The aim of this work was to evaluate the effects of orally administered citral in experimental models of acute and chronic nociception, inflammation, and gastric ulcers caused by non-steroidal anti-inflammatory drugs (NSAIDs). Oral treatment with citral significantly inhibited the neurogenic and inflammatory pain responses induced by intra-plantar injection of formalin. Citral also had prophylactic and therapeutic anti-nociceptive effects against mechanical hyperalgesia in plantar incision surgery, chronic regional pain syndrome, and partial ligation of sciatic nerve models, without producing any significant motor dysfunction. In addition, citral markedly attenuated the pain response induced by intra-plantar injection of glutamate and phorbol 12-myristate 13-acetate (PMA, a protein kinase C activator), as well as by intrathecal (i.t.) injection of ionotropic and metabotropic glutamate receptor agonists (N-methyl-d-aspartic acid [NMDA] and 1-amino-1,3-dicarboxycyclopentane [trans-ACPD], respectively), substance P, and cytokine tumour necrosis factor-α. However, citral potentiated behaviours indicative of pain caused by i.t., but not intra-plantar, injection of a transient receptor potential vanilloid receptor type 1 (TRPV1) agonist. Finally, the anti-nociceptive action of citral was found to involve significant activation of the 5-HT2A serotonin receptor. The effect of citral was accompanied by a gastro-protective effect against NSAID-induced ulcers. Together, these results show the potential of citral as a new drug for the treatment of pain.